Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Compass Pathways has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before ...

A Placer County man is sharing his personal story of recovery from severe suicidal depression. David Bartley found relief in ...

Learn about five serious mental health conditions that often necessitate inpatient treatment. Understanding these challenges ...

Medical experts have begun using ketamine, an old anesthesia drug with psychedelic qualities, to help with treatment-resistant depression, post-traumatic stress disorder and anxiety. Now, doctors are ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label ...

St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...

We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with ...